In 2015, Allergan spent $560 million on Naurex, a small biotechnology company that had what appeared to be an important new treatment for depression. Brent Saunders, Allergan’s CEO, called the deal “a compelling and exciting investment,” and said it could help in the most severe, treatment-resistant cases of depression.

Not so fast. On Wednesday evening, Allergan announced the disappointing news that the lead drug from the deal, rapastinel, had failed to improve depression symptoms more than placebo when added to existing antidepressants in not one but three studies. The drug also appeared likely to fail in a fourth study testing whether it prevented relapses in patients whose depression had abated in the previous three trials, Allergan said.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy